Research
Hormonal
Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce greater body weight reduction than selective GLP-1 receptor agonists.
Tirzepatide, a dual-acting drug, is more effective for weight loss than standard GLP-1 drugs, achieving up to 21% weight loss in trials. It is taken once weekly, starting at a low dose to minimize stomach upset.
StrongSupportsVERY_HIGH confidence
there are now several dual GIP/GLP-1 receptor agonists in clinical development, including tirzepatide... One of the more recent representatives of this drug class, and the one that has been shown to exert a superior effect to GLP-1 receptor agonists in humans, is LY3298176/tirzepatide
Why this rating
Based on Phase III trials (SURPASS programme) and regulatory approval.
Source
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy
Matthias H. Tschöp et al. · Diabetologia · 2023
DOI 10.1007/s00125-023-05929-0
narrative_reviewCited 80×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →